MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14737175.2025.2599853

Медицинская библиотека · Expert review of neurotherapeutics · 2025

Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparison.

Takizawa Tsubasa, Ahmadyar Gina, Tyas Emma, Duan Molly, Ubamadu Ifeanyi, Yamazaki Toru, Jameel Haris, Chen Judy, Suzuki Keisuke, Imai Noboru, Hashimoto Yoichiro, Sanno Naoko, Igarashi Hisaka, Gandhi Pranav, Shibata Mamoru

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

This study compared the efficacy and safety/tolerability of atogepant versus rimegepant as preventive migraine treatments in Japanese patients using anchored matching-adjusted indirect comparisons (MAICs).

METHODS

Three placebo-controlled trials were included: RELEASE and PROGRESS (atogepant), and BHV3000-309 (rimegepant). Efficacy outcomes included change from baseline in mean monthly migraine days (MMDs) and mean monthly acute medication use days (MUDs). Quality-of-life endpoints included Migraine-Specific Quality-of-Life Questionnaire (MSQ) v2.1 Role Function-Restrictive (RFR) domain score, Migraine Disability Assessment (MIDAS) total score, and EQ visual analog scale (EQ-VAS) score. Safety/tolerability outcomes included treatment-emergent adverse events (AEs) and AEs leading to treatment discontinuation.

RESULTS

Atogepant demonstrated a statistically significant greater reduction from baseline in mean MMDs (mean difference [MD]: 1.33; 95% confidence interval [CI]: -2.48, -0.18) and monthly acute MUDs (MD: ‑1.97; 95% CI: -3.06, -0.87) versus rimegepant across 12 weeks; and a statistically significant greater improvement from baseline in MSQ v2.1 RFR domain score at Week 12 (MD: 4.80; 95% CI: 0.15, 9.45). No significant differences were identified for other endpoints.

CONCLUSIONS

In these MAICs, atogepant was associated with statistically significant greater reductions in MMDs and monthly acute MUDs, and greater improvements in MSQ v2.1 RFR domain scores versus rimegepant in Japanese patients with migraine.

Для цитирования: Takizawa Tsubasa, Ahmadyar Gina, Tyas Emma, Duan Molly, Ubamadu Ifeanyi, Yamazaki Toru, Jameel Haris, Chen Judy, Suzuki Keisuke, Imai Noboru, Hashimoto Yoichiro, Sanno Naoko, Igarashi Hisaka, Gandhi Pranav, Shibata Mamoru. Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparison.. Expert review of neurotherapeutics. 2025. DOI: 10.1080/14737175.2025.2599853.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.